{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:35:41Z","timestamp":1792510541680,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,14]]},"DOI":"10.7759\/cureus.31508","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T04:33:55Z","timestamp":1668486835000},"source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India"],"prefix":"10.7759","author":[{"given":"Shubhadeep","family":"Sinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumarasamy","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasanth Kumar","family":"Suram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasa S","family":"Chary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veer Bahadur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra P","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnav","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Sawardekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noushadali","family":"Sk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leela","family":"Talluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralidhar","family":"Panapakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya","family":"Vattipalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"FDA approves first treatment for COVID-19. (2020). Accessed. September 22, 2022: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-covid-19.","DOI":"10.1002\/cpu.30542"},{"key":"ref2","unstructured":"COVID-19 treatment. investigational drugs and other therapies. (2022). Accessed: September 22, 2022: https:\/\/emedicine.medscape.com\/article\/2500116-overview."},{"key":"ref3","unstructured":"FDA halts use of COVID drugs ineffective against omicron. (2022). Accessed. September 22, 2022: https:\/\/www.webmd.com\/lung\/news\/20220125\/fda_halts_covid_drugs."},{"key":"ref4","unstructured":"Coronavirus (COVID-19) update. FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against omicron variant. (2022). Accessed: September 22, 2022: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibod...."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1039\/d0cc05944g","article-title":"A concise route to MK-4482 (EIDD-2801) from cytidine","volume":"56","author":"Vasudevan N","year":"2020","unstructured":"Vasudevan N, Ahlqvist GP, McGeough CP, et al.. A concise route to MK-4482 (EIDD-2801) from cytidine. Chem Commun (Camb). 2020, 56:13363-4. 10.1039\/d0cc05944g","journal-title":"Chem Commun (Camb)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02428-20","article-title":"Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2","volume":"65","author":"Painter WP","year":"2021","unstructured":"Painter WP, Holman W, Bush JA, et al.. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021, 65:e02428-20. 10.1128\/AAC.02428-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1101\/2021.06.17.21258639","article-title":"Molnupiravir, an oral antiviral treatment for COVID-19","author":"Fischer W","year":"2021","unstructured":"Fischer W, Eron JJ, Holman W, et al.. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021, 10.1101\/2021.06.17.21258639","journal-title":"medRxiv"},{"key":"ref8","unstructured":"Merck and Ridgeback\u2019s molnupiravir, an investigational oral antiviral COVID-19 treatment, receives special approval for emergency in Japan. (2021). Accessed. September 22, 2022: https:\/\/www.businesswire.com\/news\/home\/20211224005081\/en\/."},{"key":"ref9","unstructured":"Emergency use authorization (EUA) for the emergency use of molnupiravir for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19). (2022). Accessed. September 22, 2022: https:\/\/www.fda.gov\/media\/155053\/download."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102396","article-title":"An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19","volume":"16","author":"Singh AK","year":"2022","unstructured":"Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022, 16:102396. 10.1016\/j.dsx.2022.102396","journal-title":"Diabetes Metab Syndr"},{"key":"ref11","unstructured":"Clinical guidance for management of adult COVID-19 patients, dated 22 Apr 2021. AIIMS\/ICMR-COVID-19 National Task Force\/Joint Monitoring Group (Dte. GHS). Ministry of Health and Family Welfare, Government of India. (2021). Accessed. September 22, 2022: https:\/\/dghs.gov.in\/WriteReadData\/Orders\/202104231216553337715COVIDManagementAlgorithm_22Apr21.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","unstructured":"A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020, 20.e192-7. 10.1016\/S1473-3099(20)30483-7","journal-title":"Lancet Infect Dis"},{"key":"ref13","unstructured":"World Health Organization - Uppsala Monitoring Centre System for standardised case causality assessment. (2018). Accessed. November 04, 2022: https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox RM","year":"2021","unstructured":"Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021, 6:11-8. 10.1038\/s41564-020-00835-2","journal-title":"Nat Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer WA 2nd","year":"2022","unstructured":"Fischer WA 2nd, Eron JJ Jr, Holman W, et al.. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022, 14:eabl7430. 10.1126\/scitranslmed.abl7430","journal-title":"Sci Transl Med"},{"key":"ref16","unstructured":"Merck and Ridgeback Biotherapeutics provide update on results from MOVe-OUT study of molnupiravir, an investigational oral antiviral medicine, in at risk adults with mild-to-moderate COVID-19. (2021). Accessed. September 22, 2022: https:\/\/www.merck.com\/news\/merck-and-ridgeback-biotherapeutics-provide-update-on-results-from-move-out-study-of-molnu...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/118243-efficacy-and-safety-of-molnupiravir-in-mild-covid-19-patients-in-india","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:34Z","timestamp":1707508174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/118243-efficacy-and-safety-of-molnupiravir-in-mild-covid-19-patients-in-india"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,14]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.31508","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,14]]}}}